林松文，博士，副研究员，硕士研究生导师。2011年毕业于北京大学药学院，获得化学生物学博士学位。2011至2013年在北京大学&方正医药研究院联合工作站从事博士后研究工作。2015年9月进入bobapp官方下载 工作至今，先后任助理研究员、副研究员，主要从事创新药物研发等方面的工作。近年来，作为项目/任务负责人先后承担了中国博士后基金、北京市博士后基金、国家“十三五”重大新药创制专项（子任务）等科研任务。近年来发表SCI论文10余篇，其中作为第一作者/共同第一作者在J. Med. Chem., Eur. J. Med. Chem., J. Control. Release, Bioorg. Med. Chem., Bioorg. Med. Chem. Lett.等杂志发表论文10篇。申请发明专利10余项。

以分子靶向药物为主要研究领域，开展小分子靶向抗肿瘤药物和自身免疫性疾病治疗药物等新药研发工作；在此基础上，进行PROTAC分子的设计、合成和活性评价，探索PROTAC技术在各种疾病中的应用；同时，针对肿瘤组织的特殊性，开展抗肿瘤药物的靶向递送和释放技术研究，提高抗肿瘤药物的疗效和安全性。

1. Lin, S.#; Jin, J.#; Liu, Y.#; Tian, H.; Zhang, Y.; Fu, R.; Zhang, J.; Wang, M.; Du, T.; Ji, M.; Wu, D.; Zhang, K.; Sheng, L.; Li, Y.; Chen, X.*; Xu, H.* Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. J. Med. Chem. 2019, 62, 8873-8879. (# Co-First Authors；封面文章)
2. Lin, S.#; Wang, C.#; Ji, M.; Wu, D.; Lv, Y.; Zhang, K.; Dong, Y.; Jin, J.; Chen, J.; Zhang, J.; Sheng, L.; Li, Y.; Chen, X.*; Xu, H.* Discovery and optimization of 2-amino-4-methylquinazoline derivatives as highly potent phosphatidylinositol 3-kinase inhibitors for cancer treatment. J. Med. Chem. 2018, 61, 6087–6109. (# Co-First Authors)
3. Lin, S.#; Li, Y.#; Zheng, Y.; Luo, L.; Sun, Q.*; Ge, Z.; Cheng, T.; Li, R.* Design, synthesis and biological evaluation of quinazoline–phosphoramidate mustard conjugates as anticancer drugs. Eur. J. Med. Chem. 2017, 127, 442-458 (# Co-First Authors)
4. Lin, S.#; Wang, C.#; Ji, M.; Wu, D.; Lv, Y.; Sheng, L.; Han, F.; Dong, Y.; Zhang, K.; Yang, Y.; Li, Y,; Chen, X.*; Xu, H.* Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. Bioorg. Med. Chem. 2018, 26, 637–646. (# Co-First Authors)
5. Han, F.#; Lin, S.#; Liu, P.; Liu, X.; Tao, J.; Deng, X.; Yi, C.; Xu, H.* Discovery of a novel series of thienopyrimidine as highly potent and selective PI3K inhibitors. ACS Med. Chem. Lett., 2015, 6, 434-438. (# Co-First Authors)
6. Lin, S.#; Han, F.#; Liu, P.; Tao, J.; Zhong, X.; Liu, X.; Yi, C.*; Xu, H.* Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 790-793. (# Co-First Authors)
7. Han, F.#; Lin, S.#; Liu, P.; Tao, J.; Yi, C.*; Xu, H.* Synthesis and structure–activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives. Bioorg. Med. Chem. Lett. 2014, 24, 4538-4541. (# Co-First Authors)
8. Lin, S.; Wang, N.; Zhao, S.; Sun, Q.; Zhang, W.; Ye, J.; Cheng, T.; Li, R.* Synthesis and analgesic evaluation of a series of proline-typed spiro cyclic quaternary ammoniums. Med. Chem. Res. 2014, 23, 862-869.
9. Liang, L.#; Lin, S.#; Lu, J.; Yang, T.; Xiang, Y.; Li, R.*; Zhang, Q.* Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity. J. Control. Release 2012, 160, 618-629. (# Co-First Authors)
10. Lin, S.; Sun, Q.; Ye, J.; Wang, X.; Ge, Z.; Li, R.* Synthesis and structure-analgesic activity relationships of a novel series of monospirocyclopiperazinium salts (MSPZ). Bioorg. Med. Chem. Lett. 2011, 21, 940-943.
11. Sun, Y.; Fu, R.; Lin, S.; Zhang, J.; Ji, M.; Zhang, Y.; Wu, D.; Zhang, K.; Tian, H.; Zhang, M.; Sheng, L.; Li, Y.; Jin, J.; Chen, X.; Xu, H. Discovery of New Thieno[2,3-d]pyrimidine and Thiazolo[5,4-d]pyrimidine Derivatives as Orally Active Phosphoinositide 3-Kinase Inhibitors. Bioorg. Med. Chem. 2021, 29, 115890.
12. Du, T.; Lin, S.; Ji, M.; Xue, N.; Liu, Y.; Zhang, Z.; Zhang, K.; Zhang, J.; Zhang, Y.; Wang, Q.; Sheng, L.; Li, Y.; Lu, D.*; Chen, X.*; Xu, H.* A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Cancer Lett. 2020, 495, 22–32.
13. Xia, L.; Zhang, Y.; Zhang, J.; Lin, S.; Zhang, K.; Tian, H.; Dong, Y.*; Xu, H.* Identification of novel thiazolo[5,4-b]pyridine derivatives as potent phosphoinositide 3-kinase inhibitors. Molecules 2020, 25, 4630
14. Dong, Y.; Zhang, X.; Chen, J.; Zou, W.; Lin, S.; Xu, H.* Switching the site-selectivity of C–H activation in aryl sulfonamides containing strongly coordinating N-heterocycles. Chem. Sci. 2019, 10, 8744–8751.
15. Zhang, K.; Lai, F.; Lin, S.; Ji, M.; Zhang, J.; Zhang, Y.; Jin, J.; Fu, R.; Wu, D.; Tian, H.; Xue, N.; Sheng, L.; Zou, X.; Li, Y.; Chen, X.*; Xu, H*. Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases. J. Med. Chem. 2019, 62, 6992-7014
16. Lv, Y.; Du, T.; Ji, M.; Wang, C.; Lin, S.; Xue, N.; Jin, J.; Xu, H.; Chen, X. A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC. J. Drug Target. 2019, 27, 451-459
17. Chen, Y.; Ji, M.; Zhang ,S.; Xue, N.; Xu, H.; Lin, S.; Chen, X. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. J. Drug Target. 2018, 26, 920-930.
18. Zheng, Y.; Zou, W.; Luo, L.; Chen, J.; Lin, S.; Sun, Q.* Ligand-free Cu-catalyzed O-arylation of aliphatic diols. RSC Adv. 2015, 5, 66104-66108.